ArriVent's Nasdaq Debut Nabs $175M as Signs Indicate an Opening IPO Window

ArriVent BioPharma will apply the IPO cash toward furmonertinib, which the biotech says could offer advantages over Takeda Pharmaceutical and Johnson & Johnson drugs that address the same lung cancer target. It’s the second biotech IPO of this week, following CG Oncology.

Related Keywords

China ,Japan ,Japanese ,Arrivent Biopharma ,Johnson Rybrevant ,Allist Pharma ,Newtown Square ,Nasdaq ,Federal Reserve ,Pennsylvania Based Arrivent ,Shanghai Based Allist ,Alto Neuroscience ,Metagenomi Technologies ,Weight Loss ,Obesity ,Verweight ,Diabetes ,Massachusetts ,Medical Devices ,Startups ,Healthcare Innovation ,Medcity News ,San Francisco ,Life Sciences ,Accelerator ,Rock Health ,Startup Advice ,Startup Funding ,Patient Monitoring System ,Otion Sensors ,Dc ,Healthcare It ,Washington ,Foodborne Pathogens ,Iagnostics Company ,Iagnostic Platforms ,Minimally Invasive Surgery ,Aser Surgery ,Cambridge ,Dealflow ,Hospitals ,Wellpoint ,Ealthways ,Ealth And Wellness ,Mployee Wellness Programs ,Investing ,Wellness ,Medtronic ,Hanghai Innovation Center ,R D ,Mdt ,Minneapolis ,Minnesota ,Publics ,Twin Cities ,Ulcerative Colitis ,Abbott Labs ,Humira ,Doctors ,Pharmaceuticals ,Skin Disorders ,D Anderson Cancer Center ,Cancer ,Texas ,Renal Denervation ,St Jude Medical ,Stj ,Emr ,Hr ,Electronic Health Records ,Electronic Medical Records ,Certified Emr ,Ehr ,Advanced Cellular Technology ,Amyotrophic Lateral Sclerosis ,Embryonic Stem Cells ,Geron Corporation ,Lou Gehrigs Disease ,Macular Degeneration ,Regenerative Medicine ,Spinal Cord Damage ,Value Based Healthcare System ,Obamacare ,Ee For Service Model ,California ,Cleveland ,Health Insurance ,Insurance ,Ohio ,Pennsylvania ,Politics ,Cancer Treatment Options Library ,Aetna ,Pet ,Aet ,Health It ,Phi ,Philadelphia ,Biopharma Nl ,Biotech Ipo ,Dancer ,Clinical Trials ,Non Small Cell Lung Cancer , ,